Alex Fotopoulos
Chief Tech/Sci/R&D Officer at PASSAGE BIO, INC.
Net worth: 96 005 $ as of 29/04/2024
Alex Fotopoulos active positions
| Companies | Position | Start | End |
|---|---|---|---|
| PASSAGE BIO, INC. | Chief Tech/Sci/R&D Officer | 30/06/2019 | - |
Career history of Alex Fotopoulos
Former positions of Alex Fotopoulos
| Companies | Position | Start | End |
|---|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Chief Tech/Sci/R&D Officer | 31/10/2017 | 30/06/2019 |
| DIMENSION THERAPEUTICS INC | Chief Tech/Sci/R&D Officer | 30/04/2016 | 31/10/2017 |
| MOMENTA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/07/2011 | 30/04/2016 |
| BIOGEN INC. | Corporate Officer/Principal | 31/07/1994 | 31/12/2010 |
Training of Alex Fotopoulos
| Tufts University | Graduate Degree |
| F.W. Olin Graduate School of Business | Masters Business Admin |
Statistics
International
| United States | 8 |
Operational
| Chief Tech/Sci/R&D Officer | 4 |
| Graduate Degree | 1 |
| Masters Business Admin | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| PASSAGE BIO, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Alex Fotopoulos
- Experience
